16 marzo 2017

PM01183 // PharmaMar US . Edison Investment Aumenta en más de 1 euro el Precio Objetivo de PharmaMar y lo situa en los 5,79 euros . Valora el PM01183 en 3,61 euros y Destaca la Ultima Patente conseguida por este Farmaco que lo Proteje hasta Finales del 2032 .

PHM Pharmamar S.A.

Strong Newsflow Expected in 2017 .

PharmaMar is approaching two key.

Milestones in H217:

 * An Approval Decision for Aplidin for Multiple Myeloma in Europe .

* Phase III Results for Lurbinectedin in Ovarian Cancer.

 The Chugai licence deal for lurbinectedin in Japan has strengthened the company’s financial position (pro forma net debt €32m) and seen it put increased emphasis on its preferred strategy to either self-commercialise or co-promote lurbinectedin in the US. 

Separately, a US manufacturing patent granted last year has extended IP protection for lurbinectedin until at least December 2032.

 These developments have prompted us to adopt co-promotion in the US in our base case valuation scenario and to extend our rNPV model to 2035 vs 2030 previously. 

Our base case valuation has increased by 29% to €1.29bn (vs €1.01bn), or €5.79/share (vs €4.55/share).